Aduro BioTech is conducting a clinical trial to test an investigational new immunotherapy for malignant pleural mesothelioma (MPM). This therapy, called CRS-207, is given to a patient in combination with chemotherapy in hopes of encouraging the body’s normal defense mechanisms to fight off the cancer. This trial aims to enroll up to 60 patients at 5 U.S. clinical sites. The company presented data at the American Society of Clinical Oncology (ASCO) conference this week showing that of the 32 patients with MPM treated with CRS-207 and chemotherapy, MPM tumors reduced in size for 19 patients, and tumors remained the same size (stable) in an additional 11 patients. CRS-207 is given prior to and after chemotherapy (cyclophosphamide, pemetrexed and cisplatin) for patients who have not received prior treatment or surgery for their disease.
If you are interested in participating in a clinical trial for this investigational new therapy, please click here.
The 2015 ASCO Annual Meeting, one of the largest oncology meetings of the year, was held from May 29 to June 2 in Chicago, Illinois. The Meso Foundation will be providing more information on studies presented at ASCO in the coming weeks.
